Gene profiling in early stage disease

Cancer Journal

Volumn 16, Issue 3, 2010, Pages 210-213

  Midgley, Rachel ^a   Rasul, Kakil ^b   Al Salama, Haitham ^a,c   Kerr, David J ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Al Amal Hospital   (United Kingdom)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Adjuvant therapy; Colorectal cancer; Gene profile

Indexed keywords

BIOLOGICAL MARKER;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SAMPLE SIZE;

COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 77953631539     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181e07606     Document Type: Review

References (12)

1. Gray R, Barnwell J, McConkey C, et al. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet. 2007;370:2020-2029.
2. Gray RG, Kerr DJ, McConkey CC, et al. On behalf of QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higherdose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet. 2000;355:1588-1596.
3. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104: 57-64.
4. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044-1048.
5. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995;55:5217-5221.
6. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumour site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518-7528.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
8. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
9. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Eng J Med. 2004;351: 2817-2826.
10. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes B colon cancer. J Clin Oncol. 2004;27:1564-1571.
11. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumour gene expression profiling. J Clin Oncol. 2006;24:4685-4691.
12. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol. 2009;27 (suppl 15):abstract 4000.